SATISFYER_1170x120_8-13-20

Stelara (ustekinumab)

Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life

Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life

BASEL — Novartis announced Tuesday additional results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering specific quality of life (QoL) aspects in adults with moderate-to-severe plaque psoriasis at 16 weeks. New CLARITY data show over two-thirds of Cosentyx treated patients with moderate to severe psoriasis reported no impact of